Bing

SEARCH HISTORY

USA Today Traders work on the floor of the New York Stock Exchange. (Photo ... Friday, one of the big earnings disappointments was the biotechnology company Biogen (BIIB), which sent its shares tumbling 21% after it reported second-quarter results …
USA Today · 7/24/2015
Biogen (BIIB) more than halved its revenue growth forecast for 2015 and its stock lost 22 percent to close just above $300. You got underwhelming revenue growth on balance and then you layer on top of that concern over a global economic slowdown ...
Daily Finance · 7/24/2015
CAMBRIDGE, Massachusetts — Biogen cut its full-year adjusted profit forecast Friday as sales of one of its multiple ... But the reduced forecast weighed on the stock. Biogen's shares declined $64.47, or 16.8 percent, to $320.58 in morning trading.
tribtown.com · 7/24/2015
Last week was a less-than-ideal one for Biogen ($BIIB)--and the Massachusetts company may risk becoming ... frenzy that whittled $20 billion in market value off the company's stock, some analysts say Biogen could become a takeover target if it doesn ...
FiercePharma · 7/29/2015
And when I wrote this article back in August, the involvement of one of the world’s largest financial institutions in these “dead money” investments was making its stock, well, a “dead money” investment, too. One reader in particular wasn’t too ...
Trefis · 12/27/2013
On the other hand, shares of Biogen (BIIB) may come under pressure after the biotechnology ... S&P 500 dropped 12.00 points or 0.6 percent to 2,102.15. In overseas trading, stock markets across the Asia-Pacific region moved the downside during trading ...
Realtime Business News · 7/25/2015
NEW YORK (TheStreet) -- Shares of Biogen Idec Inc. are up 2.10% to $315.30 in pre-market trade after J.P. Morgan upgraded the stock to "overwight" from "neutral" and raised its price target to $375 from $300, based on "multiple mid-stage pipeline ...
MSN · 5/29/2014
Biogen (BIIB.O) more than halved its revenue growth forecast for 2015 and its stock lost 22 percent to close just above USD 300. Stocks in the energy and materials sectors weighed heavily on the market after weaker-than-expected economic data from …
Money Control · 7/26/2015
Biogen Idec could win the race to crack the Alzheimer’s drug market. On Friday, Biogen (ticker: BIIB) delivered clinical trial results for BIIB-037, boosting confidence in its experimental treatment for the progressive, memory-eating disorder associated ...
Barron's · ByJohanna Bennett · 3/21/2015
It's viewed as institutional buying because the stock has shown some strength by finishing well off its low for the week. An example often helps, so look at Biogen Idec's (BIIB) action in late 2010 and early 2011. Then, there was more light volume ...
Investor's Business Daily · ByVictor Reklaitis · 8/11/2015

Biogen Idec

Company
Biogen is a global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and deliver…
Biogen is a global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
Data from: Wikipedia · Freebase